J.M.KAYAbout

J.M.Kay

Jonathan Kay

Founder and Principal, J.M.Kay. Formerly Senior Director, Global External Communications, AstraZeneca.

For six years at AstraZeneca I advised leaders of its oncology research and then its rare disease business on what they said in public: before congresses and interviews, in the annual report, through the loss of Oncology R&D’s leader and through the integration of Alexion. Earlier I counseled Amgen, Takeda and Roche Diagnostics from Singapore. In 2025 I founded J.M.Kay, which builds the record before it writes the story.

About

The discipline came first

I began as a researcher. After neuroscience and psychology at Brandeis I joined the Framingham Heart Study, where I conducted more than a hundred neuropsychological examinations and wrote each up as a narrative report for the study’s senior investigators. I have written for that reader ever since.

Health sciences communications followed, in New York, Singapore and Los Angeles. In Edelman’s BioScience practice I helped public companies, AstraZeneca among them, prepare for high-profile announcements and for the issues that could follow them. Edelman then moved me to Singapore to lead its health sciences practice for Southeast Asia, with a remit that reached across Asia, the Middle East and Africa. I advised the regional chief executives of pharmaceutical and health companies, worked with government health officials and the leaders of health nonprofits, and co-wrote the firm’s report on Singapore’s health reforms. At KYNE I helped open the Los Angeles office and, as vice president, ran its operations and key accounts.

At AstraZeneca I first led science communications for Oncology R&D. I developed a model for taking a medicine’s science narrative from research to the commercial business and, with the business development and transactions teams, handled the communications around oncology deals. In 2021 the company gave me its Global Corporate Affairs Award for the communications plan I led when Oncology R&D suddenly lost its leader. As senior director of global external communications I then built and led editorial for the rare disease business, a unit with more than seven billion dollars in annual revenue, with the team and agency budgets behind it. I was the lead for its part of the annual report, working with investor relations, and I led the unit’s communications through a change of senior leadership. Much of what I wrote at AstraZeneca went first to investor relations or to legal, compliance and regulatory reviewers, who could check it.

About

The practice

J.M.Kay writes what an organization has to stand behind in public, and builds the record under it first, whether the reader who will check it is an analyst, a regulator, a reporter or a town. It works in four ways, from a four-week audit of one document to a full narrative with the record under it, all on one method and to a published standard. In 2026 I designed and led the research behind a global technology company’s narrative program in three communities on two continents, and I now oversee the research as the program expands into nine more markets. When a client asks what its record will support, I go and find out.

Every engagement runs on a written record, so no step depends on anyone’s memory and the work can be picked up where it stands. AI tools do much of the routine work under my direction, to written procedures, and every decision is mine. Two rules hold throughout: a client’s material serves only that client’s work, and before anything leaves, an automated check stops any page that contains a name or a figure the client has not cleared.

About

On film

José Baselga, the oncologist who led AstraZeneca’s cancer research, died in 2021. I created, executive produced and co-wrote José Baselga: Cancer’s Fiercest Opponent, a sixty-minute documentary about his life, made with the trust of his family and the colleagues who knew him, presented by AstraZeneca and directed by Chris Valentino. It was selected for the Boston Film Festival and the Barcelona International Film Festival and nominated for a PRWeek award. I also created Ask a Scientist, a series in which AstraZeneca’s scientists answered plain questions about their research.